Philippines Pharma and Healthcare Sector Report 2025-2026

The Philippines' healthcare system comprises both public and private components. Public healthcare is devolved to local government units, with the central government operating only a handful of tertiary care and specialist health facilities. Devolution has led to healthcare fragmentation, resulting in substantial disparities in the quality and availability of care among different regions. Due to persistent government underfunding, the private healthcare system has been instrumental in expanding healthcare capacity in recent years. In 2019, the government enacted the Universal Health Care Act to grant all Filipinos access to publicly funded health insurance, which should raise the demand for new healthcare facilities and equipment.

This report provides a complete and detailed analysis of the "Pharmaceuticals production" sector for Philippines. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Pharmaceuticals production" sector in Philippines
• Crystallise the forces both driving and restraining this sector in Philippines
• Ascertain Philippines’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in Philippines.
• Build a clear picture of trends, output and consumption for specific sub-sectors